Patents by Inventor Satoshi Komoriya

Satoshi Komoriya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210053965
    Abstract: It is an object of the present invention to provide a new compound capable of efficiently inducing differentiation from pluripotent stem cells into insulin-producing cells. The object of the present invention is achieved by a compound represented by formula (I): wherein R1, R2, R3, n and A have the same meanings as defined in the description, respectively, or a salt thereof.
    Type: Application
    Filed: January 18, 2019
    Publication date: February 25, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Toshihiro Kiho, Tatsuya Yano, Satoshi Komoriya, Taisaku Tanaka
  • Patent number: 10808006
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: October 20, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • Publication number: 20190233466
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Application
    Filed: February 15, 2019
    Publication date: August 1, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • Patent number: 10253060
    Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 9, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
  • Patent number: 10208082
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: February 19, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • Publication number: 20180016298
    Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 18, 2018
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
  • Patent number: 9796752
    Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: October 24, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
  • Publication number: 20170260228
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Application
    Filed: September 9, 2015
    Publication date: September 14, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • Publication number: 20160297849
    Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
    Type: Application
    Filed: March 18, 2014
    Publication date: October 13, 2016
    Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayamu Lizuka, Yasunori Ono
  • Publication number: 20140142096
    Abstract: A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure.
    Type: Application
    Filed: November 19, 2013
    Publication date: May 22, 2014
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hisashi Takahashi, Satoshi Komoriya, Takahiro Kitamura, Takashi Odagiri, Hiroaki Inagaki, Toshifumi Tsuda, Kiyoshi Nakayama, Makoto Takemura, Kenichi Yoshida, Rie Miyauchi, Masatoshi Nagamochi
  • Patent number: 8618094
    Abstract: A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: December 31, 2013
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hisashi Takahashi, Satoshi Komoriya, Takahiro Kitamura, Takashi Odagiri, Hiroaki Inagaki, Toshifumi Tsuda, Kiyoshi Nakayama, Makoto Takemura, Kenichi Yoshida, Rie Miyauchi, Masatoshi Nagamochi
  • Patent number: 8476429
    Abstract: An intermediate for production of a quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: July 2, 2013
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hisashi Takahashi, Hiroaki Inagaki, Satoshi Komoriya, Makoto Takemura, Rie Miyauchi
  • Publication number: 20130029977
    Abstract: A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure.
    Type: Application
    Filed: July 2, 2009
    Publication date: January 31, 2013
    Inventors: Hisashi Takahashi, Satoshi Komoriya, Takahiro Kitamura, Takashi Odagiri, Hiroaki Inagaki, Toshifumi Tsuda, Kiyoshi Nakayama, Makoto Takemura, Kenichi Yoshida, Rie Miyauchi, Masatoshi Nagamochi
  • Publication number: 20120232288
    Abstract: An intermediate for production of a quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria.
    Type: Application
    Filed: April 25, 2012
    Publication date: September 13, 2012
    Applicant: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Hisashi TAKAHASHI, Hiroaki INAGAKI, Satoshi KOMORIYA, Makoto TAKEMURA, Rie MIYAUCHI
  • Patent number: 8211910
    Abstract: A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: July 3, 2012
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Hisashi Takahashi, Hiroaki Inagaki, Satoshi Komoriya, Makoto Takemura, Rie Miyauchi
  • Publication number: 20120108582
    Abstract: A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure.
    Type: Application
    Filed: July 2, 2009
    Publication date: May 3, 2012
    Inventors: Hisashi Takahashi, Satoshi Komoriya, Takahiro Kitamura, Takashi Odagiri, Hiroaki Inagaki, Toshifumi Tsuda, Kiyoshi Nakayama, Makoto Takemura, Kenichi Yoshida, Rie Miyauchi, Masatoshi Nagamochi
  • Publication number: 20110312990
    Abstract: A compound represented by the general formula (1): -Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof.
    Type: Application
    Filed: December 13, 2010
    Publication date: December 22, 2011
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
  • Publication number: 20110077266
    Abstract: The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism.
    Type: Application
    Filed: May 21, 2010
    Publication date: March 31, 2011
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
  • Patent number: 7842818
    Abstract: The present invention provides a method for effectively producing an optically active form of tetrasubstituted-5-azaspiro[2.4]heptane derivative, which serves as a useful production intermediate for quinolonecarboxylic acid antibacterial agents, and intermediates for the derivative. The present invention is directed to a method for producing a compound (VII) according to the following scheme.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: November 30, 2010
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hisashi Takahashi, Rie Miyauchi, Yasuyuki Takeda, Kazuo Kanai, Junichi Kuroyanagi, Satoshi Komoriya, Makoto Takemura
  • Publication number: 20100099660
    Abstract: A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing is provided.
    Type: Application
    Filed: December 16, 2009
    Publication date: April 22, 2010
    Applicant: DAIICHI PHARMACEUTICAL CO., LTD.
    Inventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono